Hemophilia B causes a deficiency in factor IX, a protein necessary for blood clotting. Replacement factor IX therapy is the gold standard treatment, but novel and genetic therapies are showing promise ...

A long-acting coagulation factor treatment of patients with hemophilia B is safe and effective for preventing bleeding events, according to an article published online December 4 and in the December ...

Idelvion (coagulation factor IX [recombinant], albumin fusion protein) is a prescription drug used to treat and help prevent bleeding episodes in people with hemophilia B. Idelvion is given as an ...

The projected cost reductions held both for patients switching from a different extended-half-life product and for patients switching from a standard-half-life product. Switching patients with ...

Credit: Chowdary P, et al, NEJM, 2022. Hemophilia B is a rare X-chromosome-linked bleeding disorder caused by mutations in the blood clotting factor IX that reduce its circulating levels in blood. A ...

The gene therapy improved annualized bleed rates, though a handful of study participants resumed factor IX prophylaxis. A new report says the gene therapy fidanacogene elaparvovec (Beqvez) appears to ...

The clinical diagnostic industry is on the verge of a recombinant protein revolution. Recombinants have been available for decades and have served some sectors of diagnostics quite well, but they have ...

The host cell system is a critical determinant of recombinant protein quality and yield, with direct influence on protein folding and post-translational modification factors that shape the ...